Melanoma Clinical Trial
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Summary
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Diagnosis of RA or PsA
≥18 years at index treatment initiation
Participants starting treatment with:
abatacept
non-targeted DMARDs
targeted DMARD
Exclusion Criteria:
- Not applicable
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
Local Institution
Princeton New Jersey, 08540, United States
Princeton New Jersey, 08540, United States
How clear is this clinincal trial information?
